Assistant Professor, Neurology, Mayo Medical School
Neurology
Dr. Joon H. Uhm, MD
|
|
Give Review
Doctor Joon H. Uhm, MD practices Neurology. Dr. Joon H. Uhm is a published physician as well. He has 30 publications published. The latest was: The role of integrins in the malignant phenotype of gliomas. He is registered with Medicare and accepts Medicare payments.
Publications
- A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
- The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic Astrocytoma.
- Adult Low-grade Glioma: 19-year Experience at a Single Institution.
- Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial.
- Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis.
- Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients.
- Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma.
- Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic Astrocytoma.
- Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
- Cerebrovascular events after bevacizumab treatment: an early and severe complication.
- Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious ...
- North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination with Radiation Therapy in Patients with Newly Diagnosed...
- Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.
- Central Nervous system tumors.
- Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against Gliomas with increased tumor specificity.
- Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.
- The neurocognitive effects of radiation in adult low-grade glioma patients.
- Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies.
- Enhanced protein kinase C activity correlates with the growth rate of malignant Gliomas in vitro.
- Elevated levels of Mr 92,000 type IV collagenase during tumor growth in vivo.
- Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death.
- The role of integrins in the malignant phenotype of Gliomas.
- Primary diffuse leptomeningeal gliomatosis.
- Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors.
- Clinical Reasoning: a 52-year-old man with spells of altered consciousness and severe headaches.
- PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.
- Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N''-cyclohexyl-N-nitrosurea, vincristine...
- Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group...
- Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.
Conditions Treated
- Acute Kidney Failure
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Nephrology
- Oncology
- Neurology
Accepted Insurances
- Choice Plus POS II
- American Enterprise Group
- American Republic
- Assurant Health
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Cross Accord
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Golden Rule
- HealthPartners
- Choice Care PPO
- Medica
- Medical Mutual of Ohio
- Medicare MCR
- Medico
- Meritain Health
- MultiPlan PPO
- PHCS Network PPO
- Priority Health
- Thrivent Financial
- Choice Plus POS
- Options PPO
- United Healthcare
- Wisconsin Physicians Service
Education
-
McGill University Faculty of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1902883572 | |
| NPPES Provider LastName | UHM | |
| NPPES Provider FirstName | JOON | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Neurology | |
| Total Claim Count | 377.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 3.45 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1902883572 |
| Last Name Of The Provider | UHM |
| First Name Of The Provider | JOON |
| View All |
Similar Doctors
|
|
Dr. Brian P. O'Neill, MD |
|
|
Dr. James T. McCarthy, MD |
|
|
Dr. Jimmy R. Fulgham, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. James R. Gregoire, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Burton M. Onofrio, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Adam J. Loavenbruck, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ladan Zand, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kamel A. Gharaibeh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Moses Rodriguez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles D. Kassardjian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth A. Coon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Eoin P. Flanagan, MB BCH
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Hugo Botha, MB CHB
This Doctor is OpenDoctor Recommended.
|